Results 231 to 240 of about 261,948 (310)
Anti-survival of motor neuron antibodies in rheumatic and musculoskeletal diseases: prevalence, clinical associations, and biomarker potential, with novel insights into disease activity in SLE. [PDF]
Inflamm RegenImai Y, Takeshita M, Suzuki K, Fukui H, Furuhashi K, Matsumoto K, Kikuchi J, Yoshimoto K, Kaneko Y. +8 moreeuropepmc +1 more sourceThe Potential Role of Synovial T Cell Infiltration Following Knee Joint Injury in Symptoms and Progression to Osteoarthritis
Arthritis &Rheumatology, EarlyView.Objective
Identification of osteoarthritis (OA)–specific synovial inflammatory pathways and their temporal relevance is critical for therapeutic targeting. We compared mononuclear inflammatory/immune cell responses following joint injury that does or does not lead to OA to define bona fide OA‐associated cellular events.Babak Moradi, Miriam T. Jackson, Cindy C. Shu, Susan M. Smith, Margaret M. Smith, Sanaa Zaki, Hadrian Platzer, Nils Rosshirt, David Giangreco, Carla R. Scanzello, Christopher B. Little +10 morewiley +1 more sourceMusculoskeletal diseases, infections and vaccines: state of the art, research perspectives and educational needs. [PDF]
Aging Clin Exp ResEcarnot F, Thiyagarajan JA, Barbagallo M, Barratt J, Constantinescu S, Elkayam O, Ferrucci L, Hiligsmann M, Kapetanovic M, Macchia F, Michel JP, Migliore A, Pilotto A, Sieber C, Strangfeld A, Veronese N, Vetrano DL, Maggi S, Rizzoli R. +18 moreeuropepmc +1 more sourceAnti‐Carbamylated Protein Antibodies Stabilize Carbamylated Histone H3 to Promote Synovial Activation and Neutrophil Extracellular Trap‐Mediated Bone Loss in Rheumatoid Arthritis
Arthritis &Rheumatology, EarlyView.Objective
Carbamylation, a nonenzymatic post‐translational modification, contributes to rheumatoid arthritis (RA) pathogenesis. Anti‐carbamylated protein antibodies (anti‐CarP) occur in around 50% of patients with RA and associate with greater joint damage. Neutrophil extracellular traps (NETs) are a major source of carbamylated autoantigens. We sought Shuichiro Nakabo, Norio Hanata, Eduardo Patino‐Martinez, Ronald Holewinski, Ana Barrera‐Vargas, Javier Merayo‐Chalico, Scott A. Coonrod, David A. Fox, Mariana J. Kaplan, Carmelo Carmona‐Rivera +9 morewiley +1 more sourceGenetic and Epidemiological Evidence Linking Respiratory and Musculoskeletal Diseases: Shared Risk Factors and Intervention Windows
Murrin O, Voller B, Woodward RM, Carrasco-Ribelles LA, Türkmen D, Gu Q, Boddy K, Farmer L, Mancini M, Khalid S, Aveyard N, Fox C, Bowden J, Dudbridge F, Lamb SE, Masoli JA, Violán C, Pilling LC, Frayling TM, Delgado J. +19 moreeuropepmc +1 more sourceMachine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration
Arthritis &Rheumatology, EarlyView.Objective
To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...Zubeyir Salis, Denis Mongin, Denis Choquette, Louis Coupal, Catalin Codreanu, Florenzo Iannone, Roberto Caporali, Tore K. Kvien, Sella Provan, Ruth Fritsch‐Stork, Dan Nordström, Nina Trokovic, Karel Pavelka, Jakub Závada, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Irini Flouri, Céline Lamacchia, Michele Iudici, Delphine Courvoisier, Kim Lauper, Axel Finckh +22 morewiley +1 more sourceNerve Growth Factor is Sufficient to Cause Multiple Osteoarthritis‐Relevant Pathologic Features in Naïve Murine Knee Joints
Arthritis &Rheumatology, EarlyView.Objective
Nerve growth factor (NGF), a key mediator of pain, is increased in osteoarthritic (OA) joints. Antibodies against NGF show analgesic effects in painful knee OA, but clinical development was stopped because of side effects in the joints. Knowledge about the biologic effects of NGF on joint tissues is limited. Therefore, we explored the effects Alia M. Obeidat, Michael D. Newton, Jun Li, Baofeng Hu, Shingo Ishihara, Lindsey Lammlin, Lucas M. Junginger, Easton C. Farrell, Lai Wang, Frank C. Ko, Richard J. Miller, Carla R. Scanzello, Tristan Maerz, Rachel E. Miller, Anne‐Marie Malfait +14 morewiley +1 more sourceEffective Performance of the 2022 American College of Rheumatology/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in Pediatric Patients: An ARChiVe Study
Arthritis &Rheumatology, EarlyView.Objective
To assess the 2022 American College of Rheumatology (ACR)/EULAR classification criteria for antineutrophil cytoplasmic antibody–associated vasculitis (AAV) in children with chronic small‐to‐medium vessel vasculitis. Methods
A cohort of 574 patients, identified by physician's diagnosis (MD‐diagnosis) in A Registry of Childhood Vasculitis, was ...David A. Cabral, Else S. Bosman, Nick McPhate, Simranpreet K. Mann, Kirandeep K. Toor, Kimberly A. Morishita, Raashid Luqmani, Michael W. Beresford, James Bistolarides, Sarah Campillo, Sirirat Charuvanij, Kathryn Cook, Paul Dancey, Marietta de Guzman, Samundeeswari Deepak, Barbara Eberhard, Melissa Elder, Samuel Gagne, Katie Harrison, Adam Huber, Archana Khan, Susan Kim, Marisa S. Klein‐Gitelman, Tzielan C. Lee, Suzanne C. Li, Neil Martin, Flora McErlane, L. Nandini Moorthy, Alvaro H. Orjuela, Jonathan Park, Phil Riley, Alan M. Rosenberg, Susan Shenoi, Vidya Sivaraman, Sodality Sutnga, Tamara Tanner, Stacey E. Tarvin, Marinka Twilt, Linda Wagner‐Weiner, Rae S. M. Yeung, Kelly L. Brown, for the ARChiVe Investigators Network within the PedVas Initiative +41 morewiley +1 more source